Anti-Inflammatory Treatment of COVID-19 Pneumonia With Tofacitinib Alone or in Combination With Dexamethasone is Safe and Possibly Superior to Dexamethasone as a Single Agent in a Predominantly African American Cohort

OBJECTIVE: To explore the survival benefit of tofacitinib in addition to dexamethasone in hospitalized patients treated for coronavirus disease 2019 (COVID-19)–related pneumonia. PATIENTS AND METHODS: This is a single-center retrospective observational study. All patients who were hospitalized at De...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayek, Maroun E., Mansour, Michael, Ndetan, Harrison, Burkes, Quentin, Corkern, Robert, Dulli, Ammar, Hayek, Reya, Parvez, Karim, Singh, Satwinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998063/
https://www.ncbi.nlm.nih.gov/pubmed/33817559
http://dx.doi.org/10.1016/j.mayocpiqo.2021.03.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998063/
https://www.ncbi.nlm.nih.gov/pubmed/33817559
http://dx.doi.org/10.1016/j.mayocpiqo.2021.03.007

Ejemplares similares